Published in Health Business Week, August 3rd, 2007
Under the agreement, the FDA will utilize Raydiance's USP laser platform to evaluate the safety and effectiveness of high power laser-tissue interaction. The collaboration will involve the FDA's Division of Physics, Office of Science and Engineering Laboratories; Center for Devices and Radiological Health (CDRH), with hardware, software, applications and research support provided by...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.